Vivo Capital’s CureVac CVAC Stock Holding History

Vivo Capital’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-169,825	Closed	-$7.91M	–	62
2020 Q3	$7.91M	Buy	+169,825	New	+$9.47M	0.46%	44

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vivo Capital's CVAC Position: Q4 2020 in Review

Vivo Capital sold out of CureVac (CVAC) in Q4 2020, closing a stake of 169,825 shares — an estimated $7.91M sold.

Vivo Capital first reported a position in CVAC in Q3 2020 and held it in 1 quarter. The position peaked at $7.91M in Q3 2020. 61 funds tracked by Wall St. Rank hold CVAC as of Q4 2020.

Vivo Capital reported no remaining CureVac position as of Q4 2020 after selling out during the quarter.
Vivo Capital sold 169,825 CureVac shares in Q4 2020, an estimated $7.91M.
Vivo Capital first reported a position in CureVac in Q3 2020 and held it in 1 quarter.
Vivo Capital's CureVac position peaked at $7.91M in Q3 2020.
61 funds tracked by Wall St. Rank held CureVac as of Q4 2020.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.